LO CICERO, MIRKO
LO CICERO, MIRKO
DIPARTIMENTO DI SCIENZE CLINICHE "LUIGI SACCO" (attivo dal 01/01/2002 al 27/04/2012)
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral- experienced HIV-1-infected subjects treated with tenofovir combination therapy [2]
2005-10-01 M. Lo Cicero, E. Bulgheroni, F. Soster, O. Viganò, P. Cicconi, M. Galli, S. Rusconi
Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects
2002-02-01 S. Rusconi, E. Bulgheroni, S. La Seta-Catamancio, F.G. Croce, M. Lo Cicero, P.M. Citterio, M. Galli
Analysis of protease inhibitor combinations in vitro : activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates
2004-03-01 E. Bulgheroni, P. Citterio, F. Croce, M. Lo Cicero, O. Viganò, F. Soster, T.C. Chou, M. Galli, S. Rusconi
Efficacy and tolerability of multiple drug therapy in HIV-infected children
2005-01-01 A. Viganò, L. Schneider, V. Giacomet, R. Bianchi, M. Lo Cicero, F. Soster, E. Bulgheroni, S. Rusconi
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
2008-01-01 B. Vergani, M. Lo Cicero, O. Viganò, F. Sirianni, S. Ferramosca, P. Vitiello, P. Di Vincenzo, M.P. De Pasquale, M. Galli, S. Rusconi
In vitro efficacy of a non-conventional (folding) HIV-1 protease inhibitor without selection of resistance
2009-05-01 S. Ferramosca, M. Lo Cicero, A.E. Laface, F. Sirianni, E. Cesana, D. Provasi, G. Tiana, M. Galli, M. Moroni, A. Clivio, R.A. Broglia, S. Rusconi
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses
2009-05-22 S. Rusconi, M. Lo Cicero, O. Viganò, F. Sirianni, E. Bulgheroni, S. Ferramosca, A. Bencini, A. Bianchi, L. Ruiz, C. Cabrera, J. Martinez-Picado, C.T. Supuran, M. Galli
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro
2007-01-01 S. Rusconi, M. Lo Cicero, S. Ferramosca, S. Sirianni, M. Galli, M. Moroni, A.E. Laface, E. Cesana, A. Clivio, G. Tiana, D. Provasi, R.A. Broglia
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro
2007-01-01 S. Rusconi, M. Lo Cicero, S. Ferramosca, S. Sirianni, M. Galli, M. Moroni, A.E. Laface, E. Cesana, A. Clivio, G. Tiana, D. Provasi, R.A. Broglia
The non-conventional (folding) protease inhibitor blocks the human immunodeficiency virus type-1 replication without evidence of resistance during in vitro passage
2008-01-01 S. Ferramosca, M. Lo Cicero, A.E. Laface, F. Sirianni, E. Cesana, D. Provasi, G. Tiana, M. Galli, M. Moroni, A. Clivio, R.A. Broglia, S. Rusconi